Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $7.65, but opened at $8.10. Telix Pharmaceuticals shares last traded at $8.3260, with a volume of 104,984 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TLX. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $8.36 and its two-hundred day moving average price is $10.13.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $213,000. Blair William & Co. IL purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $217,000. JPMorgan Chase & Co. bought a new position in shares of Telix Pharmaceuticals in the 3rd quarter worth $243,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.